Description
A common metabolic pathway for several prostaglandins (PGs), including PGD
2, involves the reduction of the double bond between C-
13 and C-
14 and oxidation of the hydroxyl group at C-
15, producing 13,14-
dihydro-
15-
keto PGs. The removal of four carbons at the α-
terminus and oxidation of the terminal ω-
carbon produces the abundant urinary metabolites, including tetranor-
PGDM. 13,14-
dihydro-
15-
keto-
tetranor PGD
2 is a potential metabolite of PGD
2. It would be produced from the known metabolite 13,14-
dihydro-
15-
keto PGD
2 , which is a known agonist for the CRTH2/DP
2 receptor.